Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy.

The utility of fractional exhaled nitric oxide ( We examined the utility of FeNOSuppT in prediction of progression to biologic agents or discharge from specialist care. FeNOSuppT was measured at home using remote monitoring technology of inhaler use alongside daily Of the 162 subjects, 135 successfully completed the test with 81 (60%) positive A negative FeNOSuppT correlates with progression to biologic therapy. A positive FeNOSuppT, with subsequent maintenance of "optimised"

Informations de copyright

Copyright ©The authors 2021.

Déclaration de conflit d'intérêts

Conflict of interest: C.A. Butler reports Vitalograph provided support for the INCA device used to assess adherence during the conduct of the study; and fees for lectures from AstraZeneca and GlaxoSmithKline, and conference support from NAPP and Chiesi, outside the submitted work. Conflict of interest: A.J. McMichael has nothing to disclose. Conflict of interest: K. Honeyford has nothing to disclose. Conflict of interest: L. Wright has nothing to disclose. Conflict of interest: J. Logan has nothing to disclose. Conflict of interest: J. Holmes has nothing to disclose. Conflict of interest: J. Busby has nothing to disclose. Conflict of interest: C.E. Hanratty has nothing to disclose. Conflict of interest: F. Yang has nothing to disclose. Conflict of interest: S.J. Smith has nothing to disclose. Conflict of interest: K. Murray has nothing to disclose. Conflict of interest: R. Chaudhuri reports advisory board meeting fees, a research grant, speaker fees and conference travel support from AstraZeneca; advisory board meeting and speaker fees from GSK, Teva, Novartis and Chiesi; and conference travel support from Napp Pharmaceuticals, all outside the submitted work. Conflict of interest: L.G. Heaney reports sponsorship for attending international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; personal fees for lectures and advisory boards from Novartis, Hoffman la Roche/Genentech Inc., Sanofi, Evelo Biosciences, GlaxoSmithKline, AstraZeneca, Teva, Theravance and Circassia; and institutional grant funding from Medimmune, Novartis UK, Roche/Genentech Inc. and GlaxoSmithKline; and is Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma, which involves Industrial Partnerships with Amgen, Genentech/Hoffman la Roche, AstraZeneca, Medimmune, GlaxoSmithKline, Aerocrine and Vitalograph, all outside the submitted work.